Naoko Takebe to Aged, 80 and over
This is a "connection" page, showing publications Naoko Takebe has written about Aged, 80 and over.
Connection Strength
0.866
-
Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors. Clin Cancer Res. 2021 07 15; 27(14):3834-3844.
Score: 0.128
-
Identification of high-risk drugs related to chemotherapy-induced peripheral neuropathy?in Cancer Therapy Evaluation Program-sponsored phase I trials. Eur J Cancer. 2019 07; 115:111-119.
Score: 0.113
-
Potential utility of a longitudinal relative dose intensity of molecularly targeted agents in phase 1 dose-finding trials. Cancer Sci. 2018 Jan; 109(1):207-214.
Score: 0.102
-
Drug induced interstitial lung disease in oncology phase?I trials. Cancer Sci. 2016 Dec; 107(12):1830-1836.
Score: 0.095
-
Analysis of esophagogastric cancer patients enrolled in the National Cancer Institute Cancer Therapy Evaluation Program sponsored phase 1 trials. Gastric Cancer. 2017 May; 20(3):481-488.
Score: 0.093
-
Phase II Study of Defactinib (VS6063) in Patients With Tumors With NF2 Loss: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol U. JCO Precis Oncol. 2024 Dec; 8:e2400327.
Score: 0.041
-
Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors. Clin Cancer Res. 2024 May 01; 30(9):1739-1749.
Score: 0.040
-
The Exceptional Responders Initiative: Feasibility of a National Cancer Institute Pilot Study. J Natl Cancer Inst. 2021 01 04; 113(1):27-37.
Score: 0.032
-
Phase IB Study of Osimertinib in Combination with Navitoclax in EGFR-mutant NSCLC Following Resistance to Initial EGFR Therapy (ETCTN 9903). Clin Cancer Res. 2021 03 15; 27(6):1604-1611.
Score: 0.031
-
The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design. J Natl Cancer Inst. 2020 10 01; 112(10):1021-1029.
Score: 0.031
-
Vismodegib or cixutumumab in combination with standard chemotherapy for patients with extensive-stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E1508). Cancer. 2016 Aug 01; 122(15):2371-8.
Score: 0.023
-
Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors. Ann Oncol. 2016 Feb; 27(2):318-23.
Score: 0.022
-
Pilot clinical trial of hedgehog pathway inhibitor GDC-0449 (vismodegib) in combination with gemcitabine in patients with metastatic pancreatic adenocarcinoma. Clin Cancer Res. 2014 Dec 01; 20(23):5937-5945.
Score: 0.020
-
A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients. Invest New Drugs. 2014 Oct; 32(5):1005-16.
Score: 0.020
-
GDC-0449 in patients with advanced chondrosarcomas: a French Sarcoma Group/US and French National Cancer Institute Single-Arm Phase II Collaborative Study. Ann Oncol. 2013 Nov; 24(11):2922-6.
Score: 0.019
-
Evaluation of food effect on pharmacokinetics of vismodegib in advanced solid tumor patients. Clin Cancer Res. 2013 Jun 01; 19(11):3059-67.
Score: 0.018
-
KIT as a therapeutic target in metastatic melanoma. JAMA. 2011 Jun 08; 305(22):2327-34.
Score: 0.016
-
Phase I and pharmacokinetic study of Triapine, a potent ribonucleotide reductase inhibitor, in adults with advanced hematologic malignancies. Leuk Res. 2007 Sep; 31(9):1165-73.
Score: 0.012
-
Quantitative O(6)-methylguanine DNA methyltransferase methylation analysis in curatively resected non-small cell lung cancer: associations with clinical outcome. Clin Cancer Res. 2003 Jan; 9(1):223-7.
Score: 0.009